newsfilter
← Latest News
GlobeNewswire·

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced